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Abstract: An antituberculosis activity test of N-p-Methylbenzyl-p-coumaramide (MBC) against M. 
tuberculosis H37Rv has been carried out. The purpose of this study was to determine the 
antituberculosis activity of MBC against M. tuberculosis H37Rv. The study was conducted using 
agar diffusion method. The test solution was prepared by dissolving MBC in 20 mL Ogawa medium 
to a final concentration of 0.25; 0.50; 1; and 2 mg/L. PDA media that had been inoculated with M. 
tuberculosis H37Rv (seeded agar) were poured over the base layer on the petridish surface. Paper 
disks that have been immersed in the test solution were put symmetrically on the seeded agar. 
Furthermore, the seeds were incubated at 37 oC for 48 hours. Then the diameter of the inhibition 
zone was measured to the accuracy of 0.5 mm with a ruler. The results showed that MBC has 
biological activity as an antituberculosis. MBC can inhibit the growth of M. tuberculosis H37Rv at 
a concentration of 0.25; 0.50; 1; and 2 mg/L with a diameter of inhibitory zones respectively 8.9; 
13.7; 18.5; and 21.3 mm. This showed that the inhibition of MBC on the growth of M. tuberculosis 
H37Rv increased with increasing concentration of MBC used. 
 
Keywords: tuberkulosis (TB), antituberkulosis, N-p-Metilbenzil-p-kumaramida (MBC), M.  
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INTRODUCTION  
Tuberculosis (TB) is one of the deadliest diseases in the world caused by 
Mycobacterium tuberculosis. TB can be cured by administering appropriate 
antituberculosis. The most commonly used antituberculosis drugs are isoniazid, rifampicin, 
pyrazinamide, streptomycin, and ethambutol. These five types of drugs are referred to as 
first-line drugs (Blasko et al., 2010). The problem of TB is exacerbated by the presence of 
M. tuberculosis strains that are resistant to two or more antituberculosis known as Multi 
Drug Resistance (MDR). The presence of M. tuberculosis resistance to antituberculosis has 
encouraged the use of other more toxic alternative drugs such as ethionamide, 
aminosalicylic acid, cycloserine, capreomycin, ciprofloxacin, and nofloxacin. These six 
types of drugs are referred to as second-line drugs. Provision of a more toxic drug is of 
course more dangerous because the drug can have greater side effects on its users. The TB 
problem is further compounded by the discovery of M. tuberculosis which is also resistant 
to a second-line drug called Extreme Drug Resistance (XDR) (Retnoningrum et al., 2004). 
Therefore, research on TB is very active, especially in the field of development and 
discovery of new drugs with maximum inhibition and toxicity that is safe for the body. 
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There are five commonly used antituberculosis drugs namely isoniazid (INH), 
rifampicin, pyrazinamide, streptomycin, and ethambutol (Figure 1). For active TB, these 
five antituberculosis drugs are often used together. Combination therapy is used to prevent 
the development of drug resistance and shorten the duration of treatment. The resistance of 
M. tuberculosis to these five antituberculosis drugs develops rapidly if used without other 
antibiotics, with an estimated rate of resistance in the laboratory between 10−7 to 10-10 per 
TB bacteria per generation. As for latent TB, the five antituberculosis drugs are often used 
alone. These five antituberculosis drugs can also be used to treat non-tuberculosis 
mycobacterial infections, such as M. avium, M. kansasii, M. bovis, M. leprae and M. xenopi 
(Wikipedia, 2019). The five compounds below can be used as a reference in synthesizing 








d. Rifampicin  e. Streptomycin 
 
Figure 1. Structure of five first-line antituberculosis drugs (Wikipedia, 2019) 
 
(Dali & Dali, 2017) has successfully synthesized the N-p-methylbenzyl-p-kumaramide 
(MBC) compound from p-coumaric acid and p-methylbenzylamine using an orthoboric 
acid catalyst (Figure 2). 
 
 
Figure 2. Synthesis of the reaction of the compound N-p-methylbenzyl-p-coumaramide from p-coumaric acid 
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MBC compounds are included in amide derived compounds which have hydroxyl 
functional groups. The MBC compound has a structural similarity to the five 
antituberculosis compounds above because the five compounds also belong to a group of 
amine and amide derivatives which have hydroxyl functional groups. Therefore, MBC 
compounds are potentially used as antituberculosis drugs. 
 
RESEARCH METHODS 
Materials and Tools 
MBC is synthesized by referring to the method reported by Dali (2017). p-coumaric 
acid p.a., p-methylbenzylamine p.a., H3BO3 p.a., N,N-dimethylformamide (DMF) p.a., 
diethylether p.a., Na2SO4 anhydrous p.a., chloroform p.a., acetone p.a., aquabidest (Onelab 
Waterone), TLC plate, filter paper (paper disk), sodium chloride, glycerol, eggs, Potato 
Dextrose Agar (PDA), isoniazid (INH), Loewenstein Jensen medium, Middlebrook 7H9 
medium, and M. tuberculosis H37Rv culture obtained from the American Type Culture 
Collection (Rockville, Md.). Chemicals are ordered from Merck and/or Sigma Aldrich. 
Three-neck rounded bottom flask, condenser, analytical balance (Ohaus), Celsius 
thermometer, magnetic stirrer, heating mantle, desiccator, refrigerator, sterile cupboard, 




Synthesis of N-p-methylbenzyl-p-coumaramide (MBC) from p-Coumaric Acid 
A total of 0.5 g (3 mmol) of p-coumaric acid was put into a 100 mL three-neck 
rounded bottom flask equipped with a condenser. A total of 0.037 g (0.6 mmol) orthoboric 
acid and 30 mL DMF were added to the three-neck rounded bottom flasks until it dissolved. 
Then 0.849 g (3 mmol) of p-methylbenzylamine are added to the mixture. Then the mixture 
is stirred and refluxed for 24 hours at room temperature. Every 2 hours the mixture was 
TLC tested. Reflux is stopped after the reaction product is formed, then the solution is 
cooled to room temperature. 10 mL cold aquabidest was added to the solution, then the 
solution was extracted with 3 x 30 mL diethylether. The organic phase is dried with 
anhydrous Na2SO4, then the water free organic phase is evaporated until yellow solids are 
formed. Next the yellow solid is recrystallized with chloroform and acetone to form a white 
solid (Dali & Dali, 2017). 
 
Manufacture of PDA Media 
PDA media are made by suspending 17.55 g of PDA in 450 mL of aquabidest (39 g 
in 1000 mL of water). Then the PDA media is heated using a hot plate until it boils and 
dissolves completely. After that, the PDA media is allowed to stand and sterilized in an 
autoclave at 121 oC and 1 atm pressure for 15 minutes (Firdaus et al., 2011). 
 
Manufacture of Ogawa Medium 
Every 3.75 g of Lowenstein Jensen medium was dissolved in 600 mL aquabidest and 
12 mL glycerol. The medium was sterilized in an autoclave for 15 minutes at 121oC, then 
the medium was cooled to 50oC on a hotplate. A total of 5 eggs which have been 
homogenized were added to the medium. Then the medium is stirred with a magnetic stirrer 
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Preparation of M. tuberculosis H37Rv Inoculum  
M. tuberculosis H37Rv culture was grown on Middlebrook 7H9 liquid media with 
Oleic Acid Bovine Serum Albumin Dextrose Catalase (OADC) complex at 37oC and 
strongly agitated once a day. For inoculums, M. tuberculosis H37Rv suspension was made 
in NaCl 0.85 on turbidity of Standard No. 1 McFarland (OD 0.257 at 600 nm) containing 
about 3 x 108 CFU/mL (Andrews, 2001). 
 
Preparation of Medium Containing MBC 
A total of 20 mL of Ogawa medium was put into 4 erlenmeyers. MBC was added to 
erlenmeyer 1 to a final concentration of 0.25 mg/L. MBC was added to erlenmeyer 2 to a 
final concentration of 0.50 mg/L. MBC was added to erlenmeyer 3 to a final concentration 
of 1 mg/L. MBC was added to erlenmeyer 4 to a final concentration of 2 mg/L. The four 
mediums are homogeneously sterile with a magnetic stirer. Each medium was piped 5 mL 
sterically and put in 4 test tubes. The negative control used was 5 mL of Ogawa medium 
without the addition of M. tuberculosis H37R and MBC cultures. While the positive control 
used was a mixture of 3 mL Ogawa medium, 1 mL INH, and 1 mL culture of M. 
tuberculosis H37R. Then the medium was tilted and inspected in an incubator at 85oC for 
48 hours (Rattan et al., 1998). 
 
Antituberculosis Activity Test 
PDA media as a base layer are poured into petridish aseptically. A total of 20 mL of 
PDA media was put into an effendorf tube. Then 10 L of M. tuberculosis H37Rv inoculum 
was added to the effendorf tube. Furthermore, the mixture is homogeneously sterile with a 
magnetic stirer. A total of 5 mL of PDA media that had been inoculated with M. 
tuberculosis H37Rv (seeded agar) was poured on top of the base layer in a circular motion 
until seeded agar so that it was docked on the petridish surface. Then seeded agar to stand 
for a few minutes until solidified. Paper disks that have been immersed in the test solution 
(0.25; 0.50; 1; 2) mg/L are placed symmetrically with a distance of at least 20 mm from 
the petridish edge. Test solutions, negative controls, and positive controls of 20 L were 
dripped with a sterile pipette on the paper disk. The tip of the pipette is used to press the 
paper disk on the seeded agar. Next petridish closed tightly. After that, the seeded agar are 
incubated at 37 °C for 48 hours or until the growth of the colony can be observed with the 
eye. The diameter of the inhibition zone is measured to the nearest 0.5 mm with a line or 
colony counter. The results are positive if there is no growth of the colony in the media. 
On the other hand, the results would be negative if there was a growth in the media colony 
(Dali & Dali, 2004). 
 
RESULTS AND DISCUSSION 
Synthesis Results 
The MBC compounds obtained were in the form of white solid (yield 75.83%), 
melting point 156-158oC, and TLC (SiO2, n-hexane : chloroform = 5 : 3 v/v, Rf = 0.37) 
(Dali & Dali, 2017). 
 
Antituberculosis Activity Test Results 
The results of measurement of inhibition zone diameters from MBC are presented in 
Table 1. From Table 1 it appears that the higher the concentration of MBC used, the wider 
the diameter of the inhibition zone obtained. This shows that the inhibitory power of MBC 
on the growth of M. tuberculosis H37Rv increases with increasing concentration of MBC 
used. 
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Obstacles Experiment Reference* 
Ogawa Medium + 
MBC 
0,25 8,9 6-10 Weak 
0,50 13,7 11-15 Medium 
1 18,5 16-20 Strong 
2 21,3  21 Very Strong 
Positive Control 
(Ogawa Medium + 
INH + M. tuberculosis 
culture) 
- 17,5 16-20 Strong 
Negative Control 
(Ogawa Medium) 
- 0  5 None 
*Source: Rastina et al., 2015. 
 
The mechanism of action of MBC as an antituberculosis is that the MBC interacts 
with the transmembrane protein (porin) on the outer membrane of the M. tuberculosis 
H37Rv cell wall to form a strong hydrogen bond between the carbonyl group (C=O) of 
MBC with the NH group of porin and/or the NH group of MBC with the C=O group of 
porin, resulting in damage to porin (Figure 3). As a result, M. tuberculosis H37Rv cells 
will lack nutrients, so the growth of M. tuberculosis H37Rv can be inhibited or die. 
 
 
Figure 3. Interaction of hydrogen bonds between C=O and NH groups of MBC with NH and C=O groups of 
transmembrane protein (porin) 
 
The cell wall of M. tuberculosis H37Rv is composed of bag-shaped a single molecule 
that surrounds the cell membrane and is called peptidaglycan. The peptidaglycan repeating 
unit is tetrapeptide (Figure 4). Tetrapeptides are peptide molecules composed of four amino 
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of these two groups, tetrapeptides can form cross-link with heteropolysaccharide-peptide 
chains parallel to the oligopeptide bridge (Page, et al., 1989). 
 
 
Figure 4. Peptidaglycan repeating unit of M. tuberculosis H37Rv cell wall (Page, et al., 1989) 
 
The mechanism of action of MBC as an antituberculosis is by inhibiting the 
formation of peptidaglycan in the M. tuberculosis H37Rv cell wall (Figure 5), so that the 
M. tuberculosis H37Rv cell wall layer is not formed intact and causes the death of the M. 
tuberculosis H37Rv cells. 
 
 
Figure 5. Inhibition of the formation of peptidaglycan in M. tuberculosis H37Rv cell walls by forming cross-
link of heteropolysaccharide-MBC chains 
 
The use of INH as a positive control because INH is one of the first-line 
antituberculosis drugs. The mechanism of action of INH as an antituberculosis is by 
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INH is activated by the enzyme catalase-peroxidase of bacterium in M. tuberculosis H37Rv 
called KatG [35]. The second stage, KatG catalyzes the formation of isonicotinic acyl 
radicals which spontaneously pair with NAD+ to form nicotinoyl-NAD+ complexes. In the 
third stage, the nicotinoyl-NAD+ complex is closely bound to the enzyme enoyl-[acyl-
carrier-protein] reductase [NADH] or InhA, which prevents the enoyl-ACP reductase 
[NADH] substrate reacting with the enzyme fatty acid synthase-I (FAS-I). This process 
inhibits the synthesis of mycolic acid, which is a required component of the M. tuberculosis 




Figure 6. Mechanism of action of INH as antituberculosis (Wikipedia, 2019) 
 
CONCLUSIONS 
MBC compounds have biological activity as antituberculosis. MBC can inhibit the 
growth of M. tuberculosis H37Rv at a concentration of 0.25; 0.50; 1; and 2 mg/L with a 
diameter of inhibitory zones respectively 8.9; 13.7; 18.5; and 21.3 mm. This shows that the 
inhibition power of MBC on the growth of M. tuberculosis H37Rv increases with 
increasing concentration of MBC used. 
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